NetFlix Inc vs Zoetis Inc — how do they compare? NetFlix Inc trades at $68.14 (market cap $281.48B), while Zoetis Inc trades at $76.07 (market cap $31.95B). The key difference: NetFlix Inc is far larger — about 8.8× Zoetis Inc's market cap, and Zoetis Inc pays a 2.78% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals.
| NFLX | ZTS | |
|---|---|---|
Market Cap | $281.48B | $31.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $126.33 | $156.76 |
52-Week Low | $67.60 | $71.91 |
Enterprise Value | $286.66B | $39.24B |
Dividend Yield | — | 2.78% |
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) is trading at $68.95, down 7.26% over 24 hours and approaching its 52-week low. The stock shows bearish technical signals with oversold RSI levels, while fundamentals remain strong with Q1 2026 EPS beating expectations at $1.23 versus $0.763. Revenue grew to $45.18B in 2025 with a net income margin of 24.3%, though valuation ratios like P/E of 21.26 and P/S of 6.02 suggest moderate pricing. Recent news highlights stock declines despite business growth, with focus on advertising expansion and content performance.
The outlook for NFLX is mixed; strong earnings and ad-tier scalability offer upside, but technical weakness and competitive pressures pose risks. Analysts maintain a buy consensus with a $90.47 price target, implying significant potential appreciation. Key risks include market sentiment shifts and execution challenges in new revenue streams, requiring careful monitoring of quarterly results and subscriber trends.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →